Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629844 | 0.84 | CYP1A2 (0.31) | — | |
| SCHEMBL6152174 | 0.84 | CYP1A2 (0.31) | — | |
| SCHEMBL2318595 | 0.76 | CYP1A2 (0.32) | — | |
| SCHEMBL4311977 | 0.76 | — | — | |
| SCHEMBL2411016 | 0.75 | CYP1A2 (0.32) | — | |
| SCHEMBL386156 | 0.74 | CYP1A2 (0.55) | AHR | |
| SCHEMBL2256346 | 0.74 | ALDH1A1 (0.55) | PARP1MEN1KMT2A | |
| SCHEMBL8071828 | 0.74 | CYP3A4 (0.31) | — | |
| SCHEMBL25231782 | 0.74 | SLC9A1 (0.33) | BACE1MEN1KMT2A | |
| SCHEMBL386939 | 0.73 | HSD17B10 (0.44) | PARP1PLAUMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576543-B1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2016-12-21 | — | — | EP | claimed |
| US-9181195-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-11-10 | — | — | US | claimed |
| US-8927570-B2 | 1-naphthyl-or 1-dihydroacenaphthenyl-pyrido[B]indoles and uses thereof in treating cancers | BUOLAMWINI JOHN K (US) | 2015-01-06 | — | — | US | claimed |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | claimed |
| US-20130131070-A1 | 1-Aryl or 1- Heteroaryl-Pyrido(B)indoles and Uses Thereof | BUOLAMWINI JOHN K (US) | 2013-05-23 | — | — | US | claimed |
| EP-2576543-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | Laboratorios del Dr. Esteve S.A. (ES) | 2013-04-10 | — | — | EP | claimed |
| CN-103003267-A | Sigma receptor inhibitors | ESTEVE LABOR DR | 2013-03-27 | — | — | CN | claimed |
| EP-2395003-A1 | Pyrazole compounds as sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-12-14 | — | — | EP | claimed |
| WO-2011147910-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-12-01 | — | — | WO | claimed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| US-4906753-A | Preparation of 2,6-disubstituted-5-cyano-4-pyrimidinyloxyacetic acid aldose reductase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-03-06 | — | — | US | claimed |
| US-4786640-A | TREATMENT OR PREVENTION OF DIABETIC COMPLICATIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-11-22 | — | — | US | claimed |
| US-4786638-A | TREATMENT OR PREVENTION OF DIABETIC COMPLICATIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-11-22 | — | — | US | claimed |
| US-3993645-A | Stilbene optical brighteners and compositions brightened therewith | STERLING DRUG INC. (US) | 1976-11-23 | — | — | US | claimed |
| US-3932301-A | NYLON, POLYESTERS | STERLING DRUG INC. (US) | 1976-01-13 | — | — | US | claimed |
| CN-118234761-A | Process for producing modified conjugated diene polymer, polymer composition, crosslinked material, and tire | 株式会社引能仕材料 | 2024-06-21 | — | — | CN | disclosed |
| US-3993645-A | Stilbene optical brighteners and compositions brightened therewith | STERLING DRUG INC. (US) | 1976-11-23 | — | — | US | disclosed |
| US-3932301-A | NYLON, POLYESTERS | STERLING DRUG INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | PARP1 4373/4885AHR 1057/4885NOS1 1279/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | PARP1 346/4885AHR 2425/4885NOS1 317/4885 |
| US-20130131070-A1 | 1-Aryl or 1- Heteroaryl-Pyrido(B)indoles and Uses Thereof | HRH3, HRH4, CNR1 | PARP1 2453/4885AHR 12/4885NOS1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.